{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:53:40Z","timestamp":1792457620517,"version":"4.5.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lipidjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.jacl.2016.06.006","type":"journal-article","created":{"date-parts":[[2016,6,25]],"date-time":"2016-06-25T22:17:01Z","timestamp":1466893021000},"page":"1137-1144.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Effects of the cholesteryl ester transfer protein inhibitor, TA-8995, on cholesterol efflux capacity and high-density lipoprotein particle subclasses"],"prefix":"10.1016","volume":"10","author":[{"given":"Julian C.","family":"van Capelleveen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.P.","family":"Kastelein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aeilko H.","family":"Zwinderman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sander J.H.","family":"van Deventer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi L.","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven J.","family":"Adelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Round","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Ford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Rader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Kees","family":"Hovingh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.jacl.2016.06.006_bib1","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1001\/jama.2009.1619","article-title":"Major lipids, apolipoproteins, and risk of vascular disease","volume":"302","author":"Di Angelantonio","year":"2009","journal-title":"JAMA"},{"issue":"9943","key":"10.1016\/j.jacl.2016.06.006_bib2","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/S0140-6736(14)61217-4","article-title":"HDL and cardiovascular disease","volume":"384","author":"Rader","year":"2014","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.jacl.2016.06.006_bib3","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","article-title":"Effects of torcetrapib in patients at high risk for coronary events","volume":"357","author":"Barter","year":"2007","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.jacl.2016.06.006_bib4","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa1206797","article-title":"Effects of dalcetrapib in patients with a recent acute coronary syndrome","volume":"367","author":"Schwartz","year":"2012","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jacl.2016.06.006_bib5","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of extended-release niacin with laropiprant in high-risk patients","volume":"371","author":"Parish","year":"2014","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.jacl.2016.06.006_bib6","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1161\/CIRCULATIONAHA.111.066589","article-title":"Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport","volume":"125","author":"Rosenson","year":"2012","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.jacl.2016.06.006_bib7","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1056\/NEJMoa1001689","article-title":"Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis","volume":"364","author":"Khera","year":"2011","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.jacl.2016.06.006_bib8","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1056\/NEJMoa1409065","article-title":"HDL cholesterol efflux capacity and incident cardiovascular events","volume":"371","author":"Rohatgi","year":"2014","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.jacl.2016.06.006_bib9","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S2213-8587(15)00126-6","article-title":"Association of HDL cholesterol efflux capacity with incident coronary heart disease events: a prospective case-control study","volume":"3","author":"Saleheen","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"10.1016\/j.jacl.2016.06.006_bib10","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nrcardio.2015.124","article-title":"Dysfunctional HDL and atherosclerotic cardiovascular disease","volume":"13","author":"Rosenson","year":"2016","journal-title":"Nat Rev Cardiol"},{"issue":"4","key":"10.1016\/j.jacl.2016.06.006_bib11","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1161\/ATVBAHA.109.199158","article-title":"The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages","volume":"30","author":"de la Llera-Moya","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"10.1016\/j.jacl.2016.06.006_bib12","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1373\/clinchem.2010.155333","article-title":"HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events","volume":"57","author":"Rosenson","year":"2011","journal-title":"Clin Chem"},{"issue":"25","key":"10.1016\/j.jacl.2016.06.006_bib13","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1056\/NEJMoa1009744","article-title":"Safety of anacetrapib in patients with or at high risk for coronary heart disease","volume":"363","author":"Cannon","year":"2010","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.jacl.2016.06.006_bib14","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1001\/jama.2011.1649","article-title":"Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial","volume":"306","author":"Nicholls","year":"2011","journal-title":"JAMA"},{"issue":"15","key":"10.1016\/j.jacl.2016.06.006_bib15","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1056\/NEJMp048023","article-title":"Increasing HDL cholesterol levels","volume":"350","author":"Brewer","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2016.06.006_bib16","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/S0140-6736(15)60158-1","article-title":"Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial","volume":"386","author":"Hovingh","year":"2015","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.jacl.2016.06.006_bib17","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1161\/01.ATV.20.12.2670","article-title":"Distribution of ApoA-I-containing HDL subpopulations in patients with coronary heart disease","volume":"20","author":"Asztalos","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"27","key":"10.1016\/j.jacl.2016.06.006_bib18","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1093\/eurheartj\/ehu105","article-title":"The effect of cholesteryl ester transfer protein inhibition on lipids, lipoproteins, and markers of HDL function after an acute coronary syndrome: the dal-ACUTE randomized trial","volume":"35","author":"Ray","year":"2014","journal-title":"Eur Heart J"},{"issue":"7","key":"10.1016\/j.jacl.2016.06.006_bib19","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1161\/ATVBAHA.110.207142","article-title":"Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib","volume":"30","author":"Yvan-Charvet","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"20","key":"10.1016\/j.jacl.2016.06.006_bib20","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1016\/j.jacc.2015.09.013","article-title":"Cholesterol efflux capacity and pre-beta-1 HDL concentrations are increased in dyslipidemic patients treated with evacetrapib","volume":"66","author":"Nicholls","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.jacl.2016.06.006_bib21","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S0022-2275(20)30184-X","article-title":"ApoA-I secretion from HepG2 cells: evidence for the secretion of both lipid-poor apoA-I and intracellularly assembled nascent HDL","volume":"43","author":"Chisholm","year":"2002","journal-title":"J Lipid Res"},{"issue":"1","key":"10.1016\/j.jacl.2016.06.006_bib22","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.bbrc.2008.11.146","article-title":"Formation of preB1-HDL during lipolysis of triglyceride-rich lipoprotein","volume":"379","author":"Miyazaki","year":"2009","journal-title":"Biochem Biophys Res Commun"},{"issue":"6","key":"10.1016\/j.jacl.2016.06.006_bib23","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1172\/JCI80025","article-title":"Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects","volume":"125","author":"Millar","year":"2015","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jacl.2016.06.006_bib24","series-title":"Lilly to discontinue development of evacetrapib for high-risk atherosclerotic cardiovascular disease","year":"2015"},{"key":"10.1016\/j.jacl.2016.06.006_bib25","series-title":"Annual Scientific Sessions of the American College of Cardiology (ACC)","article-title":"Impact of the cholesteryl ester transfer protein inhibitor evacetrapib on cardiovascular outcome","author":"Nicholls","year":"2016"},{"key":"10.1016\/j.jacl.2016.06.006_bib26","series-title":"Merck provides update on REVEAL Outcomes Study","year":"2015"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287416302252?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287416302252?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,2]],"date-time":"2022-07-02T05:15:14Z","timestamp":1656738914000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287416302252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["S1933287416302252"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2016.06.006","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of the cholesteryl ester transfer protein inhibitor, TA-8995, on cholesterol efflux capacity and high-density lipoprotein particle subclasses","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2016.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 National Lipid Association. All rights reserved.","name":"copyright","label":"Copyright"}]}}